24. JoyL Silva, GM, and Nicole Strauss Pipeline Development and Innovation Lead, Pfizer CentreOne
Biotech 2050 Podcast29 Heinä 2020

24. JoyL Silva, GM, and Nicole Strauss Pipeline Development and Innovation Lead, Pfizer CentreOne

JoyL is the General Manager of Pfizer CentreOne, a global contract development and manufacturing organization (CDMO) and a leading supplier of specialty APIs embedded within Pfizer. In 2019, under her leadership, Pfizer CentreOne contributed $810M in revenue with a growth rate of 9% while advancing Pfizer’s purpose of delivering breakthroughs that change patients’ lives. In 2020 Pfizer CentreOne received the Life Science Leader and Outsourced Pharma CMO Leadership Award for the fourth consecutive year, recognizing the strong partnerships built with customers. JoyL began her 20+ year career at Pfizer as a healthcare representative and progressed through a series of sales, operational, and strategic leadership roles. Her roles as U.S. Regional Business Director and Commercial Enablement Lead included managing people leaders and demonstrating commercial excellence. Growing in both partnership and organizational management skills, JoyL then became the Global Integration Lead for the Pfizer/Merck KGaA Immuno-Oncology Alliance and Global Operations Lead for Pfizer Essential Health. JoyL was recently named on the Medicine Maker Power List and Putnam Media Top 20 Influential Women in Manufacturing List. She has also received a Rising Star Award by the Healthcare Businesswomen’s Association and the Scrip Best Partnership Alliance Award. JoyL has several industry publications, is a frequent speaker at professional forums and is a board member for the non-profit Pharma & Biopharma Outsourcing Association. A strong proponent of diversity, she is a sought-out mentor and sponsor. JoyL is a graduate of the South Carolina Honors College at the University of South Carolina where she received a Bachelor of Science degree in Biological Sciences with a minor in Medical Humanities. Nicole is Pfizer CentreOne’s Pipeline Development and Innovation Lead. In this role, Nicole has responsibility for assessing competitive intelligence to identify growth opportunities across the Pfizer CentreOne businesses, lead technical and regulatory assessments of pipeline projects and provide development services to meet customer needs. Nicole brings a wide range of expertise to this role, including a background which covers contract manufacturing operations, procurement, business development, and sourcing strategies. Nicole joined Pfizer in 2001 as Pharmaceutical Supply Manager supporting the Parenteral Site in Carolina, Puerto Rico. In 2002, she was promoted to Category Manager in Global Procurement responsible for the identification and selection of contract manufacturers and packagers for pharmaceutical products. She joined External Supply (ES) in 2005 supporting the Divestitures and Business Development Group, and later on moved to manage contractors as an Operations Director. In 2010, Nicole was promoted to ES Strategy and Operations Management Director which included site divestiture support, sourcing, and leading the Americas Virtual Site governance. Nicole’s most recent assignment in Global External Supply included leading the implementation of SAP and partnering with tax and network strategy teams to roll out initiatives aligned with tax efficient system strategies and the standardizing/streamlining supply chain processes across the Global External Supply Virtual Sites. Nicole holds a B.S. Degree in Chemical Engineering from The Georgia Institute of Technology and an M.B.A. from The University of Delaware.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Maalis 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Helmi 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Helmi 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Tammi 21min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-hereilla
rss-duodecim-lehti
rss-poliisin-mieli
rss-ilmasto-kriisissa
tiedekulma-podcast
docemilia
hippokrateen-vastaanotolla
sotataidon-ytimessa
rss-radplus
rss-tiedetta-vai-tarinaa
rss-opeklubi
rss-kasvikutsut
rss-totuuden-liepeilla